News
MapLight Therapeutics today announced the initiation of a Phase 2 study to evaluate the efficacy, safety and tolerability of ML-007C-MA, an investigational novel M1/M4 agonist, as a potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback